Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research
mi
from
Kalamazoo, MI
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Neurological Research Center
mi
from
Hattiesburg, MS
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Neurological Research Center
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
CRI Lifetree Marlton
mi
from
Marlton, NJ
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
CRI Lifetree Marlton
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Princeton Medical Institute
mi
from
Princeton, NJ
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Princeton Medical Institute
mi
from
Princeton, NJ
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Nathan Kline Institute
mi
from
Orangeburg, NY
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Nathan Kline Institute
mi
from
Orangeburg, NY
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
University of Rochester Medical Center; Monroe Community Hospital
mi
from
Rochester, NY
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
University of Rochester Medical Center; Monroe Community Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Alzheimer's Memory Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Raleigh Neurology Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center
mi
from
Portland, OR
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Northeastern Pennsylvania Memory
mi
from
Plains, PA
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Northeastern Pennsylvania Memory
mi
from
Plains, PA
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Rhode Island Mood & Memory Research Institute
mi
from
East Providence, RI
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Butler Hospital
mi
from
Providence, RI
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Senior Adults Specialty Research
mi
from
Austin, TX
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Senior Adults Specialty Research
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Texas Neurology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Lifetree Clinical Research
mi
from
Salt Lake City, UT
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Lifetree Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Research Associates, Inc.
mi
from
Bennington, VT
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Research Associates, Inc.
mi
from
Bennington, VT
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Hospital Italiano
mi
from
Buenos Aires,
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Hospital Italiano
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated:  12/31/1969
Bioclinica Research
mi
from
Orlando, FL
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment
Status: Enrolling
Updated: 12/31/1969
Bioclinica Research
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver Anschutz Medical Campus
mi
from
Aurora, CO
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated:  12/31/1969
Howard University
mi
from
Washington,
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Status: Enrolling
Updated: 12/31/1969
Howard University
mi
from
Washington,
Click here to add this to my saved trials
Endothelial Facilitation in Alzheimer's Disease
Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  12/31/1969
UMass Medical School/ UMass Memorial Medical Center
mi
from
Worcester, MA
Endothelial Facilitation in Alzheimer's Disease
Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 12/31/1969
UMass Medical School/ UMass Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Health
mi
from
Phoenix, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Health
mi
from
Phoenix, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC Davis
mi
from
Davis, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC Davis
mi
from
Davis, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC, Irvine
mi
from
Irvine, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC Irvine
mi
from
Orange, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
UC San Francisco Memory Center
mi
from
San Francisco, CA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
UC San Francisco Memory Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Mt Sinai Medical Center
mi
from
Miami Beach, FL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Mt Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Kansas
mi
from
Kansas City, KA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Kansas
mi
from
Kansas City, KA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Jefferson
mi
from
Philadelphia, PA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Jefferson
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
Butler Hospital
mi
from
Providence, RI
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
Butler Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated:  12/31/1969
The University of Tennessee
mi
from
Knoxville, TN
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status: Enrolling
Updated: 12/31/1969
The University of Tennessee
mi
from
Knoxville, TN
Click here to add this to my saved trials